The Right to Choose to Die

Why It Matters

The debate shapes how societies balance individual autonomy with protection of vulnerable groups, influencing costly end‑of‑life care and the emergence of underground markets. Understanding the economics of MAID informs legislators on designing safeguards that maximize welfare while minimizing unintended harms.

Key Takeaways

• 12 US states plus DC permit medical aid‑in‑dying under strict criteria
• Evidence shows bans often create covert markets for end‑of‑life drugs
• Safeguards like waiting periods reduce risk of regretted assisted deaths
• Legal MAID can lower terminal‑care costs and improve patient welfare
• Alvin Roth frames MAID as a “repugnant transaction” needing market design

Pulse Analysis

The push to legalize medical aid‑in‑dying (MAID) has accelerated across North America and Europe, with 12 U.S. states, the District of Columbia, Canada, and Switzerland offering regulated pathways. Each jurisdiction defines eligibility differently—U.S. laws typically require a terminal diagnosis with a six‑month life expectancy, while Canada allows patients with irremediable conditions even if death is not imminent. Economists like Alvin Roth view MAID through the lens of “repugnant transactions,” where personal desire clashes with moral objections, prompting the need for market‑based solutions that respect autonomy while mitigating ethical concerns.

Empirical data from these jurisdictions reveal that outright bans rarely eliminate the practice; instead, they foster clandestine markets where patients obtain lethal medications through unregulated channels. Such black‑market dynamics raise safety risks and undermine public health goals. Conversely, jurisdictions with robust safeguards—multiple physician confirmations, mandatory waiting periods, and mental‑health evaluations—report lower incidences of regretted decisions and limited evidence of coercion among vulnerable groups. Moreover, allowing MAID can curtail expensive intensive‑care interventions at the end of life, delivering measurable cost savings for health systems while enhancing patient‑reported welfare.

Designing effective MAID policy hinges on precise choice architecture: the option must be presented transparently, only when clinical criteria justify discussion, and with clear procedural steps that separate assisted dying from homicide. Roth’s broader work on “repugnant transactions” suggests that similar frameworks could govern other contentious markets, such as paid organ donation or plasma compensation. As more states contemplate legislation, the economic perspective offers a data‑driven roadmap to balance liberty, protection, and fiscal responsibility, ensuring that the right to choose a dignified death does not become a loophole for exploitation.